3/12/2009

Schering-Plough received FDA clearance to market its hepatitis C drugs Pegintron and Rebetol for patients with compensated liver disease who no longer respond to previous treatment. The drugs are approved as initial treatment in patients age 3 and older.

Full Story:
Forbes

Related Summaries